GW Pharmaceuticals, a British pharmaceutical company, hoped that a new cannabis drug would have an impact on pain in cancer patients, but much to their dismay failed to do so in a clinical study. This revelation coincided with a 21% drop in their stock on Thursday.
GW was developing the drug Sativex for pain, but according to three late-stage trials found that there was no statistically significant difference between subjects receiving the drug and subjects receiving the placebo.
